News & Updates
Showing Pharmacy articles
Showing
Trastuzumab biosimilar on par with reference agent in HER2-positive gastric cancer
CT-P6, a trastuzumab biosimilar approved for the treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (AGC), is as efficacious as reference trastuzumab in terms of response rates, progression-free (PFS) and overall survival (OS), a study has shown.
Trastuzumab biosimilar on par with reference agent in HER2-positive gastric cancer
16 Feb 2022
COVID-19 infection relatively rare in vaccinated IBD patients
Patients with inflammatory bowel disease (IBD) who have completed a COVID-19 vaccine regimen have a low risk of developing COVID-19, though receipt of mRNA vaccines may offer better protection, according to a small study presented at the Crohn’s and Colitis Congress 2022.
COVID-19 infection relatively rare in vaccinated IBD patients
15 Feb 2022
Microneedle technology on par with topical steroids in nail psoriasis treatment
A novel transdermal device for the delivery of triamcinolone demonstrates efficacy comparable to that of conventional topical steroids in the treatment of nail psoriasis, according to a Singapore study.
Microneedle technology on par with topical steroids in nail psoriasis treatment
15 Feb 2022
FOLFIRINOX safe, effective in older adults with advanced pancreatic cancer
The combination therapy of 5-fluorouracil, irinotecan, leucovorin, and oxaliplatin (FOLFIRINOX) improves response and overall survival (OS) in older adults with advanced pancreatic cancer (APC), a recent study has shown.
